Investigating how THC affects immune cells in HIV-infected individuals
In vivo study of THC-induced immunogenome changes at single cell resolution in HIV-infected humans
This study is looking at how THC, the main ingredient in cannabis, affects the immune system in people with HIV, to see if it can help reduce inflammation and improve health for those living with the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10682520 on NIH RePORTER |
What this research studies
This research explores the effects of THC, the active component of cannabis, on the immune system of individuals infected with HIV. By administering THC to both HIV-infected and uninfected participants, the study aims to understand how THC alters gene expression and immune responses at a single-cell level. The researchers will analyze changes in immune cells to determine if THC can reduce inflammation associated with chronic HIV infection. This could provide insights into potential therapeutic uses of cannabinoids for managing HIV-related complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults living with HIV who are interested in exploring the effects of THC on their immune system.
Not a fit: Patients who are not infected with HIV or those who have contraindications to THC use may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that help reduce inflammation and improve health outcomes for people living with HIV.
How similar studies have performed: While prior studies have shown cannabinoids can modulate immune responses in uninfected individuals, this specific approach in HIV-infected populations is novel and has not been extensively tested.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Xu, Ke — Yale University
- Study coordinator: Xu, Ke
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.